Close Menu

NIH

PRGN-2009 showed anti-tumor activity in preclinical studies and now will be evaluated in humans as a monotherapy and in combination with a bifunctional fusion protein.

From changes in trial enrollment to increased flexibility, clinical trials in precision oncology and other fields are feeling the brunt of the ongoing COVID-19 pandemic.

The authors of the study noted that these genetic findings could guide better clinical decisions for patients and improve outcomes.